



1647

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Pang et al.

Serial No: 09/634,363

Filed: August 9, 2000

For: Methods and Reagents for Treating  
Glucose Metabolic Disorders.

Attorney Docket No. CIBT-P02-058

Art Unit: 1647

Examiner: R. DeBerry

TECH CENTER 1600/2900

AUG 09 2002


RECEIVED

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents Washington, D.C. 20231 on the date indicated below:

July 31, 2002

Date of Signature  
and of Mail Deposit

  
Brent LaBerge

Commissioner of Patents  
Washington, D.C. 20231

**RESPONSE TO RESTRICTION REQUIREMENT**

Sir:

In response to the Restriction Requirement, which was mailed from the U.S. Patent and Trademark Office on July 1, 2002, in the above-identified patent application, Applicants elect with traverse Group I, claims 1-7, drawn to methods for contacting pancreatic cells with a PYY peptide homologous to SEQ ID NO:1. Applicants elect this invention with traverse, because claims 1-12 encompass overlapping subject matter based on methods for contacting pancreatic cells. Accordingly, Groups I-III could be examined simultaneously without significant additional burden.

In addition, Applicants submit that claims 1-6 are linking claims for Groups I-III. Applicants respectfully remind the Examiner that, in accordance with MPEP 809, "should any linking claim be allowed, the restriction requirement must be withdrawn."